 The FDA removed the full clinical hold on Aprea Therapeutics Incs NASDAQ: APRE trial evaluating the combination of eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. The agency issued a clinical hold on the study in August. 